TY - JOUR
T1 - The gulf familial hypercholesterolemia registry (Gulf fh)
T2 - Design, rationale and preliminary results
AU - Al-Rasadi, Khalid
AU - Alhabib, Khalid F.
AU - Al-Allaf, Faisal
AU - Al-Waili, Khalid
AU - Al-Zakwani, Ibrahim
AU - Alsarraf, Ahmad
AU - Almahmeed, Wael
AU - Alsayed, Nasreen
AU - Alghamdi, Mohammad
AU - Batais, Mohammed A.
AU - Almigbal, Turky H.
AU - Alnouri, Fahad
AU - Kinsara, Abdulhalim
AU - Hammouda, Ashraf
AU - Awan, Zuhier
AU - Kary, Heba
AU - Elamin, Omer A.
AU - Zadjali, Fahad
AU - Al-Jarallah, Mohammed
AU - Shehab, Abdullah
AU - Sabbour, Hani
AU - Amin, Haitham
AU - Altaradi, Hani
N1 - Funding Information:
The study was financially sponsored by Sanofi. The sponsor had no role in study design, data collection, analysis and interpretation; in the writing of the report and in the decision to submit the paper for publication.
Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - To determine the prevalence, genetic characteristics, current management and outcomes of familial hypercholesterolaemia (FH) in the Gulf region. Methods: Adult (18-70 years) FH patients were recruited from 9 hospitals and centres across 5 Arabian Gulf countries. The study was divided into 4 phases and included patients from 3 different categories. In phase 1, suspected FH patients (category 1) were collected according to the lipid profile and clinical data obtained through hospital record systems. In phase 2, patients from category 2 (patients with a previous clinical diagnosis of FH) and category 1 were stratified into definitive, probable and possible FH according to the Dutch Lipid Clinic Network criteria. In phase 3, 500 patients with definitive and probable FH from categories 1 and 2 will undergo genetic testing for 4 common FH genes. In phase 4, these 500 patients with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate clinical management and cardiovascular outcomes. The Gulf FH cohort was screened from a total of 34,366 patients attending out-patient clinics. Results: The final Gulf FH cohort consisted of 3,317 patients (mean age: 47±12 years, 54% females). The number of patients with definitive FH is 203. In this initial phase of the study, the prevalence of (probable and definite) FH is 1/232. Conclusion: The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry, a first-of-a-kind multi-national study in the Middle East region, will help in improving underdiagnosis and undertreatment of FH in the region.
AB - To determine the prevalence, genetic characteristics, current management and outcomes of familial hypercholesterolaemia (FH) in the Gulf region. Methods: Adult (18-70 years) FH patients were recruited from 9 hospitals and centres across 5 Arabian Gulf countries. The study was divided into 4 phases and included patients from 3 different categories. In phase 1, suspected FH patients (category 1) were collected according to the lipid profile and clinical data obtained through hospital record systems. In phase 2, patients from category 2 (patients with a previous clinical diagnosis of FH) and category 1 were stratified into definitive, probable and possible FH according to the Dutch Lipid Clinic Network criteria. In phase 3, 500 patients with definitive and probable FH from categories 1 and 2 will undergo genetic testing for 4 common FH genes. In phase 4, these 500 patients with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate clinical management and cardiovascular outcomes. The Gulf FH cohort was screened from a total of 34,366 patients attending out-patient clinics. Results: The final Gulf FH cohort consisted of 3,317 patients (mean age: 47±12 years, 54% females). The number of patients with definitive FH is 203. In this initial phase of the study, the prevalence of (probable and definite) FH is 1/232. Conclusion: The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry, a first-of-a-kind multi-national study in the Middle East region, will help in improving underdiagnosis and undertreatment of FH in the region.
KW - CHD
KW - Cardiovascular diseases
KW - Consanguinity
KW - Familial hypercholesterolemia
KW - Middle East
KW - Registry
UR - http://www.scopus.com/inward/record.url?scp=85077055986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077055986&partnerID=8YFLogxK
U2 - 10.2174/1570161116666181005125459
DO - 10.2174/1570161116666181005125459
M3 - Article
C2 - 30289081
AN - SCOPUS:85077055986
SN - 1570-1611
VL - 18
SP - 57
EP - 64
JO - Current vascular pharmacology
JF - Current vascular pharmacology
IS - 1
ER -